ETR-based Valve

About Xeltis

Xeltis is a clinical-stage medical device company pioneering a novel approach to cardiovascular implants. Its core technology, Endogenous Tissue Restoration (ETR), utilizes a Nobel prize-winning supramolecular polymer scaffold that guides the body to regenerate a natural, living blood vessel or valve. The company's lead program, aXess, is a vascular access conduit for hemodialysis patients and has been implanted in over 180 patients, with the company securing significant funding in late 2025 to advance it toward the market. Xeltis aims to break the cycle of surgical complications and reinterventions associated with current synthetic and biological grafts.

Therapeutic Areas